biosimilar News
Most Popular biosimilar Story
Is Obama backing down on biosimilars?
Few industries were as keen to see a new healthcare reform bill pass as BIO, which had carefully shepherded a provision providing 12 years of data exclusivity for biologics through a gauntlet of... Read more...
Latest Headlines
- February 24, 2010
- February 2, 2010
- January 20, 2010
- January 19, 2010
- January 15, 2010
- December 24, 2009
- December 9, 2009
- December 7, 2009
- November 17, 2009
- October 30, 2009
- October 23, 2009
- October 15, 2009
- August 3, 2009
- July 24, 2009
- July 22, 2009
- July 15, 2009
- July 14, 2009
- July 13, 2009
- June 26, 2009
- June 10, 2009
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
